文献速递甲状腺疾病

抑制MEK信号减弱未分化甲状腺癌中的癌症干细胞活性

Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
PubMed 文献 · Thyroid · 2024-01-16

本研究探讨BRAF抑制剂达拉非尼与MEK抑制剂曲美替尼对未分化甲状腺癌细胞中癌症干细胞活性的影响。结果显示曲美替尼减弱癌症干细胞活性强于达拉非尼,联合治疗减弱癌症干细胞活性最强,其部分机制为抑制RNA聚合酶II转录活性。

要点

  • MEK抑制剂曲美替尼减弱未分化甲状腺癌癌症干细胞活性强于BRAF抑制剂达拉非尼。
  • 联合治疗减弱癌症干细胞活性最强,但未完全消除癌症干细胞活性。
  • 药物抑制癌症干细胞活性部分由减弱RNA聚合酶II转录活性介导。

核心结论

  • 未分化甲状腺癌细胞中存在癌症干细胞。
  • MEK信号抑制减弱癌症干细胞活性可部分解释联合治疗在未分化甲状腺癌患者中的疗效。
  • 药物未完全消除癌症干细胞活性,这可能解释未分化甲状腺癌患者的复发。
  • 本研究为这些药物在未分化甲状腺癌患者中疗效与局限性的分子基础提供了新见解。

研究设计与样本

  • 使用三种人未分化甲状腺癌细胞(THJ-11T、THJ-16T和8505C细胞)进行体外和体内异种移植小鼠模型研究。
  • 评估达拉非尼(BRAF激酶抑制剂)、曲美替尼(MEK抑制剂)或两药联合对癌症干细胞活性的影响,方法包括肿瘤球形成、Aldefluor检测、关键癌症干细胞标志物表达谱、免疫组化、SORE6-mCherry报告基因共聚焦成像及体内异种移植模型。

主要发现

  • BRAF抑制剂达拉非尼疗效弱,MEK抑制剂曲美替尼在减弱癌症干细胞活性方面显示强效,表现为抑制癌症干细胞标志物表达、肿瘤球形成和Aldefluor检测。
  • 使用表达荧光癌症干细胞SORE6报告基因的未分化甲状腺癌细胞,在体外和体内异种移植模型中显示癌症干细胞活性减弱程度排序为联合>曲美替尼>达拉非尼。
  • 分子分析显示这些药物抑制癌症干细胞活性部分由减弱RNA聚合酶II活性从而抑制转录所介导。

临床怎么用

  • 作者认为MEK信号抑制减弱癌症干细胞活性可部分解释联合治疗在未分化甲状腺癌患者中的疗效。
  • 作者指出药物未完全消除癌症干细胞活性,这可能解释未分化甲状腺癌患者的复发。

局限性

  • 药物未完全消除癌症干细胞活性,这可能解释未分化甲状腺癌患者的复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Anaplastic thyroid cancer (ATC) is highly aggressive and has very limited treatment options. Recent studies suggest that cancer stem cell (CSC) activity in ATC could underlie this recurrence and resistance to treatment. The recent approval by the U.S. Food and Drug Administration of the combined treatment of BRAF and MEK inhibitors for ATC patients has shown some efficacy in patients harboring the BRAFV600E mutation. However, it was unknown whether the combined treatment could affect the CSC activity. This study explores the effects of the BRAF and MEK inhibitors on CSC activity in human ATC cells. Methods: Using three human ATC cells, THJ-11T, THJ-16T, and 8505C cells, we evaluated the effects of dabrafenib (a BRAF kinase inhibitor), trametinib (an MEK inhibitor), or a combined treatment of the two drugs on the CSC activity by tumorsphere formation, Aldefluor assays, expression profiles of key CSC markers, immunohistochemistry, and in vivo xenograft mouse models. Furthermore, we also used confocal imaging to directly visualize the effects on drugs on CSCs by the SORE6-mCherry reporter in cultured cells and xenograft tumor cells. Results: The BRAF inhibitor, dabrafenib, had weak efficacy, while the MEK inhibitor, trametinib, showed strong efficacy in attenuating the CSC activity, as evidenced by suppression of CSC marker expression, tumorsphere formation, and Aldefluor assays. Using ATC cells expressing a fluorescent CSC SORE6 reporter, we showed reduction of CSC activity in the rank order of combined > trametinib > dabrafenib through in vitro and in vivo xenograft models. Molecular analyses showed that suppression of CSC activity by these drugs was, in part, mediated by attenuation of the transcription by dampening the RNA polymerase II activity. Conclusions: Our analyses demonstrated the presence of CSCs in ATC cells. The inhibition of CSC activity by the MEK signaling could partially account for the efficacy of the combined treatment shown in ATC patients. However, our studies also showed that not all CSC activity was totally abolished, which may account for the recurrence observed in ATC patients. Our findings have provided new insights into the molecular basis of efficacy and limitations of these drugs in ATC patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kimura T, Doolittle WKL, Kruhlak M, et al. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer. Thyroid. 2024. PMID: 38115586. doi:10.1089/thy.2023.0521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。